Companies · Other Health Care

Rallybio Holdings, LLC

NEW HAVEN · Other Health Care

Diligence memoA one-page analyst read on Rallybio Holdings, LLC — recommendation, valuation, rhythm, risks.
$157.8M
Total raised · real
3
Rounds
0.1×
Latest step-up
Top 3%
Sector rank · raised
Series D+
Latest stage · inferred · Wed Apr 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Rallybio Holdings, LLC looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.06× the median modeled value of Series D+ Other Health Care companies in 2022–2024 (17 peers) — value vs value, same stage and era.
Quiet
  • Last raise 2.2 yr ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Rallybio Holdings, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
8.2 yr record
Peak capital year was 2020 with $238.4M across 2 filings.
Market position
ahead of 98% of Other Health Care peers
Capital scale is ahead of 98% of Other Health Care peers; modeled value is above 72% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2020: $238.4M across 2 filings.
  • Largest single filing was $145.2M on 2020-03-27.
  • Filing rows sum to $251.0M, while canonical raised total is $157.8M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Rallybio Holdings, LLC is one of 5376 Other Health Care companies tracked from NEW HAVEN. By capital raised it ranks among the largest (ahead of 98% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2024-04-10
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2018-04-20 Raised $6.0M (real) Modeled valuation $121M (est)$6.0M$121MSeries A2018Series D+ · 2020-03-27 Raised $145M (real) Modeled valuation $3.3B (est)$145M$3.3BSeries D+2020Series C · 2020-03-27 Raised $93M (real) Modeled valuation $2.1B (est)$93M$2.1BSeries C2020Series D+ · 2024-04-10 Raised $6.6M (real) Modeled valuation $70M (est)$6.6M$70MSeries D+2024+$145M+$93M+$6.6MCumulative $251M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.0M · 2018
Series D+$145.2M · 2020no Series B / Series C on file
Bridge · Series D+-stage$93.2M · 2020smaller follow-on
Series D+ extension$6.6M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$69.6M
Base estimate est.
$35.2M
Conservative case
$99.1M
Upside case
$55.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $121.1M · 2018-04-202018Series D+ · modeled $3.3B · 2020-03-27Series C · modeled $2.1B · 2020-03-27Series D+ · modeled $69.6M · 2024-04-102024
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
80%
Survival probability
64% low · 88% high
1.23×/yr
Annual markup
1.38×/yr upside case
2.2 yr
Elapsed time used
2.2 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
24 mo
Avg between rounds
$26.4M/yr
Capital velocity
8.2 yr
On record since
2018
First round
4
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 65× above median
This company$157.8M
Sector median$2.4M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.1× of median
This company$6.6M
Sector median$123.0M
Modeled value — vs sector median (estimate, all stages) 3.1× above median
This company$69.6M
Sector median$22.1M

Raised more than 98% of sector peers (real $). Modeled value above 72% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 17.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$100.0M$1.0BCapital raised (log)United Digestive Holdings, LLC · Series D+ Raised $323.3M · modeled $4.2B (est)DispatchHealth Holdings, Inc. · Series D+ Raised $578.0M · modeled $3.7B (est)Zimmer Biomet Holdings, Inc. · Series D+ Raised $216.1M · modeled $2.9B (est)Main Street Rural, Inc. · Series D+ Raised $211.2M · modeled $2.4B (est)Richmond Buyer L.P. · Series D+ Raised $232.6M · modeled $2.2B (est)Thirty Madison, Inc. · Series D+ Raised $255.7M · modeled $1.8B (est)Ember Management Aggregator, L.P. · Series D+ Raised $129.9M · modeled $1.8B (est)Glooko, Inc. · Series D+ Raised $221.0M · modeled $1.2B (est)Renovaro Inc. · Series D+ Raised $123.3M · modeled $1.2B (est)HistoSonics, Inc. · Series D+ Raised $308.2M · modeled $1.0B (est)Ecph, Llc · Series D+ Raised $285.4M · modeled $914.9M (est)Cortica Inc. · Series D+ Raised $210.9M · modeled $757.4M (est)Rallybio Holdings, LLC (this company) Raised $157.8M · modeled $69.6M (est)Rallybio Holdings, LLC
CompanyStageRaised · realValue · estvs peer med.
United Digestive Holdings, LLCSeries D+$323.3M$4.2B3.63×
DispatchHealth Holdings, Inc.Series D+$578.0M$3.7B3.17×
Zimmer Biomet Holdings, Inc.Series D+$216.1M$2.9B2.50×
Main Street Rural, Inc.Series D+$211.2M$2.4B2.07×
Richmond Buyer L.P.Series D+$232.6M$2.2B1.93×
Thirty Madison, Inc.Series D+$255.7M$1.8B1.56×
Ember Management Aggregator, L.P.Series D+$129.9M$1.8B1.55×
Glooko, Inc.Series D+$221.0M$1.2B1.05×
Renovaro Inc.Series D+$123.3M$1.2B1.00×
HistoSonics, Inc.Series D+$308.2M$1.0B0.87×
Ecph, LlcSeries D+$285.4M$914.9M0.79×
Cortica Inc.Series D+$210.9M$757.4M0.65×
Rallybio Holdings, LLC this companySeries D+$157.8M$69.6M0.06×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.0M2018-04-20$27.3M$121.1M90%
Series D+$145.2M2020-03-27$1.2B$3.3B90%
Series C$93.2M2020-03-27$621.4M$2.1B90%
Series D+$6.6M2024-04-10$55.0M$69.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.0M2018-04-20
    • First recorded raise — entered as Series A.
    • 7 investors on this round.
  2. Series D+$145.2M2020-03-27
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 24.2× larger than the prior — scaling up.
    • 28 investors on this round.
  3. Series C$93.2M2020-03-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 24 investors on this round.
  4. Series D+$6.6M2024-04-10
    • Raised again after 48 mo — slower than the ~14 mo sector norm.
    • Round 14.1× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2026 ~Q2
Modeled next raise · ~24mo cadence
$6.6M
Modeled next size est.range $6.6M$10.6M
0.1×
Last step-up
$26.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ketan Patel9 other2020-03
Kush Parmar9 other2020-03
Tim Shannon8 other2020-03
Ronald M. Hunt3 other2024-04
Ron Hunt3 other2020-03
KUSH M. PARMAR2 other2024-04
Robert Hopfner2 other2020-03
Christine A. Nash1 other2024-04
Ketan W. Patel1 other2020-03
Lucian Iancovici1 other2020-03
Tim W. Shannon1 other2020-03
HELEN M. BOUDREAU2024-04
HUI M. LIU2024-04
Jeffrey Fryer2020-03
Jeffrey M. Fryer2018-04
Jeffrey W. Fryer2020-03
JONATHAN I. LIEBER2024-04
Kush W. Parmar2020-03
LUCIAN M. IANCOVICI2024-04
Martin Mackay2020-03
MARTIN W. MACKAY2018-04
PAULA M. SOTEROPOULOS2024-04
Robert W. Hopfner2020-03
ROB K. HOPFNER2024-04
Registry & provenance

Rallybio Holdings, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1739410
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Entrada Therapeutics, Inc.PharmaceuticalsSeries D+$150.9M$3.3Bnetwork2 shared operators · same stage
Ensoma, Inc.BiotechnologySeries D+$169.6M$2.3Bnetwork2 shared operators · same stage
Avalyn Pharma Inc.BiotechnologySeries D+$244.0M$2.7Bnetwork2 shared operators · same stage
Neuronetics, Inc.Other Health CareSeries B$118.7M$332.3Mnetwork1 shared operator · same sector
Envision Rx Options Holdings, Inc.Other Health CareSeries D+$144.5M$80.0Msame sector · same stage
Intrapace IncOther Health CareSeries D+$179.1M$76.8Msame sector · same stage
Arvinas, Inc.BiotechnologySeries C$129.1M$1.3Bnetwork2 shared operators
OPE GEDC Holdings LLCOther Health CareSeries D+$215.0M$82.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Biocare Holdings, LLCOtherSeries C$1.5B85%
Revbio, Inc.Other Health CareSeries A$73.8M85%
Sativeo Investors, LLCOther Health CarePre-Seed$7.7M84%
Synvitrobio, Inc.Other Health CareSeries B$147.0M84%
MovementX, Inc.Other Health CarePre-Seed$3.1M83%
Biocardia Lifesciences, Inc.Other Health CareSeries A$88.3M82%
Onebiopharma Inc.Other Health CareSeed$74.4M82%
Vantage Holdings, Inc.Other Health CareSeries D+$3.2B82%
Frequently asked
How much funding has Rallybio Holdings, LLC raised?
Rallybio Holdings, LLC has raised approximately $157.8M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Rallybio Holdings, LLC's estimated valuation?
Provath's modeled valuation for Rallybio Holdings, LLC is approximately $69.6M (modeled range $35.2M–$99.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Rallybio Holdings, LLC at?
Rallybio Holdings, LLC's latest modeled financing stage is Series D+. Its most recent recorded round closed around Wed Apr 10.
What does Rallybio Holdings, LLC do and where is it based?
Rallybio Holdings, LLC operates in the Other Health Care sector, based in NEW HAVEN.
Explore related

See where Rallybio Holdings, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Rallybio Holdings, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.